0B68 Nevalainen, Marja - Thomas Jefferson University - Thomas Jefferson University

Marja Nevalainen, MD, PhD

Contact Dr. Nevalainen

Kimmel Cancer Center
233 S. Tenth Street, Suite 309B
Philadelphia, PA 19107

(215) 503-9250
(215) 503-9245 fax

Most Recent Peer-reviewed Publications

  1. Structure-based screen identifies a potent small molecule inhibitor of Stat5a/b with therapeutic potential for prostate cancer and chronic myeloid leukemia
  2. Jak2-Stat5a/b Signaling Induces Epithelial-to-Mesenchymal Transition and Stem-Like Cell Properties in Prostate Cancer
  3. Pharmacologic suppression of JAK1/2 by JAK1/2 inhibitor AZD1480 potently inhibits IL-6-induced experimental prostate cancer metastases formation
  4. Transcription factors Stat5a/b and Stat3 in prostate cancer growth and metastases
  5. Pharmacologic inhibition of Jak2-Stat5 signaling by Jak2 inhibitor AZD1480 potently suppresses growth of both primary and castrate-resistant prostate cancer
  6. STAT5A/B gene locus undergoes amplification during human prostate cancer progression
  7. Nuclear Stat5a/b predicts early recurrence and prostate cancer-specific death in patients treated by radical prostatectomy
  8. Signal transducer and activator of transcription-5 mediates neuronal apoptosis induced by inhibition of Rac GTPase activity
  9. Reply to A. Italiano
  10. Prolactin regulation of the prostate gland: A female player in a male game
  11. Signal transducer and activator of transcription 5a/b: Biomarker and therapeutic target in prostate and breast cancer
  12. Loss of nuclear localized and tyrosine phosphorylated Stat5 in breast cancer predicts poor clinical outcome and increased risk of antiestrogen therapy failure
  13. Targeting transcription factor stat5a/b as a therapeutic strategy for prostate cancer
  14. Robust gene network analysis reveals alteration of the STAT5a network as a hallmark of prostate cancer.
  15. N-terminal truncation of Stat5a/b circumvents PIAS3-mediated transcriptional inhibition of Stat5 in prostate cancer cells
  16. Activating mutation (V617F) in the tyrosine kinase JAK2 is absent in locally-confined or castration-resistant prostate cancer
  17. Stat5 promotes metastatic behavior of human prostate cancer cells in vitro and in vivo
  18. Transcription factor Stat3 stimulates metastatic behavior of human prostate cancer cells in vivo, whereas Stat5b has a preferential role in the promotion of prostate cancer cell viability and tumor growth
  19. Transcription factor Stat5a/b as a therapeutic target protein for prostate cancer
  20. Androgen-regulated and highly tumorigenic human prostate cancer cell line established from a transplantable primary CWR22 tumor